Cutera Toekomstige groei

Future criteriumcontroles 0/6

De verwachting is dat Cutera de winst en omzet met respectievelijk 26.5% en 2.4% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 34.7% per jaar.

Belangrijke informatie

26.5%

Groei van de winst

34.7%

Groei van de winst per aandeel

Medical Equipment winstgroei	17.1%
Inkomstengroei	2.4%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	11 Nov 2024

Recente toekomstige groei-updates

Recent updates

Cutera, Inc. (NASDAQ:CUTR) Looks Inexpensive After Falling 47% But Perhaps Not Attractive Enough

Aug 20

Revenues Working Against Cutera, Inc.'s (NASDAQ:CUTR) Share Price Following 28% Dive

Jun 22

Revenues Working Against Cutera, Inc.'s (NASDAQ:CUTR) Share Price Following 35% Dive

Mar 14

Analysts Are More Bearish On Cutera, Inc. (NASDAQ:CUTR) Than They Used To Be

Aug 11

An Intrinsic Calculation For Cutera, Inc. (NASDAQ:CUTR) Suggests It's 48% Undervalued

Apr 19

Cutera, Inc. (NASDAQ:CUTR) Shares Could Be 49% Below Their Intrinsic Value Estimate

Sep 01

Cutera: The 'AviClear' Sign To Get Bullish

Jun 22

Cutera (NASDAQ:CUTR) Is Carrying A Fair Bit Of Debt

May 27

Winst- en omzetgroeiprognoses

NasdaqGS:CUTR - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	160	-75	N/A	N/A	3
12/31/2025	146	-82	N/A	N/A	4
12/31/2024	141	-110	N/A	N/A	4
9/30/2024	155	-144	-120	-117	N/A
6/30/2024	169	-149	-138	-129	N/A
3/31/2024	197	-158	-161	-138	N/A
12/31/2023	212	-163	-171	-138	N/A
9/30/2023	230	-113	-160	-121	N/A
6/30/2023	247	-81	-143	-104	N/A
3/31/2023	249	-95	-107	-74	N/A
12/31/2022	252	-82	-90	-67	N/A
9/30/2022	251	-78	-62	-47	N/A
6/30/2022	245	-68	-43	-34	N/A
3/31/2022	240	-13	-31	-30	N/A
12/31/2021	231	2	0	1	N/A
9/30/2021	216	8	2	3	N/A
6/30/2021	197	7	5	6	N/A
3/31/2021	165	-12	-5	-4	N/A
12/31/2020	148	-24	-18	-17	N/A
9/30/2020	150	-28	-19	-17	N/A
6/30/2020	157	-29	-17	-16	N/A
3/31/2020	178	-17	-7	-6	N/A
12/31/2019	182	-12	-3	-2	N/A
9/30/2019	175	-37	1	2	N/A
6/30/2019	170	-35	2	3	N/A
3/31/2019	165	-37	1	2	N/A
12/31/2018	163	-31	-1	0	N/A
9/30/2018	165	18	-3	-1	N/A
6/30/2018	162	25	N/A	4	N/A
3/31/2018	156	29	N/A	8	N/A
12/31/2017	151	30	N/A	14	N/A
9/30/2017	142	11	N/A	12	N/A
6/30/2017	134	7	N/A	10	N/A
3/31/2017	125	4	N/A	2	N/A
12/31/2016	118	3	N/A	2	N/A
9/30/2016	110	0	N/A	1	N/A
6/30/2016	103	-2	N/A	-1	N/A
3/31/2016	98	-3	N/A	1	N/A
12/31/2015	95	-4	N/A	-1	N/A
9/30/2015	90	-8	N/A	-5	N/A
6/30/2015	86	-10	N/A	-5	N/A
3/31/2015	81	-11	N/A	-9	N/A
12/31/2014	78	-11	N/A	-4	N/A
9/30/2014	75	-9	N/A	-2	N/A
6/30/2014	73	-8	N/A	-1	N/A
3/31/2014	75	-6	N/A	3	N/A
12/31/2013	75	-5	N/A	4	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CUTR de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CUTR de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CUTR de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van CUTR ( 2.4% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van CUTR ( 2.4% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CUTR naar verwachting over 3 jaar hoog zal zijn

Cutera Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 16%

Cutera, Inc. Reaffirms Financial Guidance for the Full Year 2024

Cutera, Inc. Revises Revenue Guidance for the Year 2024

Price target decreased by 17% to US$6.33

Cutera, Inc. Reiterates Earnings Guidance for 2024

Cutera, Inc. Provides Revenue Guidance for the Full Year 2024

Recent updates

Cutera Receives Deficiency Notice from Nasdaq Regarding Minimum $15 Million Market Value of Publicly Held Shares Requirement under Nasdaq Marketplace Rule 5450(b)(3)(C)

Consensus EPS estimates fall by 16%

Third quarter 2024 earnings: EPS misses analyst expectations

New major risk - Market cap size

Cutera, Inc. Reaffirms Financial Guidance for the Full Year 2024

Cutera, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Cutera Receives Deficiency Notice from Nasdaq Regarding Listing Rule 5450(a)(1)

Cutera, Inc. (NASDAQ:CUTR) Looks Inexpensive After Falling 47% But Perhaps Not Attractive Enough

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Cutera, Inc. Revises Revenue Guidance for the Year 2024

High number of new and inexperienced directors

Cutera, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Cutera, Inc.(NasdaqGS:CUTR) dropped from Russell 3000 Index

Revenues Working Against Cutera, Inc.'s (NASDAQ:CUTR) Share Price Following 28% Dive

Price target decreased by 17% to US$6.33

High number of new and inexperienced directors

Cutera, Inc., Annual General Meeting, Jul 15, 2024

Cutera, Inc. Reiterates Earnings Guidance for 2024

Cutera, Inc. to Report Q1, 2024 Results on May 09, 2024

Cutera, Inc. Announces North America Launch of xeo+

Cutera, Inc. Provides Revenue Guidance for the Full Year 2024

Cutera, Inc. announced delayed annual 10-K filing

Revenues Working Against Cutera, Inc.'s (NASDAQ:CUTR) Share Price Following 35% Dive

Consensus EPS estimates fall by 33%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Cutera, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Price target decreased by 59% to US$7.67

High number of new and inexperienced directors

Cutera, Inc. Revises Revenue Guidance for the Full Year 2023

Cutera, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Annual Report on Form 10-Q

Cutera, Inc. announced delayed 10-Q filing

Cutera, Inc. Announces Resignation of Juliane Park from the Board of Directors, Effective as of December 1, 2023

Cutera, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Janet Widmann Resigns from the Board of Directors of Cutera, Inc. Effective November 1, 2023

New minor risk - Market cap size

Cutera, Inc. Appoints Brent Hauser as President, International

Cutera, Inc. Announces the Launch of New Skin Resurfacing and Revitalization Platform Secret DUO

President recently bought US$297k worth of stock

Cutera, Inc. Appoints Jeffrey Jones as Chief Operating Officer, Effective August 28, 2023

Consensus revenue estimates fall by 14%

Analysts Are More Bearish On Cutera, Inc. (NASDAQ:CUTR) Than They Used To Be

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 8.9% to US$23.00

Cutera, Inc. Provides Revenue Guidance for the Full Year 2023

Cutera, Inc. Appoints Talyor C. Harris as President, Effective August 7, 2023

Cutera, Inc. Announces CEO Changes, Effective August 7, 2023

Cutera, Inc. to Report Q2, 2023 Results on Aug 08, 2023

the Gross Law Firm Notifies Shareholders of Cutera, Inc. of A Class Action Lawsuit and A Lead Plaintiff Deadline of July 24, 2023

Cutera, Inc. Announces A New U.S. Food and Drug Administration Clearance of AviClear as A Long-Term Treatment for Mild to Severe Inflammatory Acne Vulgaris

Cutera, Inc. Announces Resignation of J. Daniel Plants as Director

Independent Director notifies of intention to sell stock

Cutera, Inc. Announces Resignation of Joseph E. Whitters from the Board of Directors

Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against Cutera, Inc

Less than half of directors are independent

Cutera, Inc. Announces Board Changes

Cutera, Inc. Appoints Stuart Drummond as Interim Chief Financial Officer

Voce Capital and David Mowry Terminate Proxy Solicitation

Cutera, Inc. Announces Chief Financial Officer Changes

First quarter 2023 earnings: EPS and revenues miss analyst expectations

An Intrinsic Calculation For Cutera, Inc. (NASDAQ:CUTR) Suggests It's 48% Undervalued

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 57%

Now 21% undervalued after recent price drop

Full year 2022 earnings: EPS misses analyst expectations

Does Cutera (NASDAQ:CUTR) Have A Healthy Balance Sheet?

Price target decreased to US$61.20

Cutera, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Cutera, Inc. Announces AviClear™ Now Broadly Available to US Physicians and Practitioners Upon National Launch